Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA; 3Real World Value and Evidence, Janssen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	rheumatoid arthritis biosimilar CT-P13 continuer treatment patterns Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e53d3e9542784a82828170823409189e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e53d3e9542784a82828170823409189e
record_format	dspace
spelling	oai:doaj.org-article:e53d3e9542784a82828170823409189e2021-12-02T07:42:19ZAnalysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab1177-5491https://doaj.org/article/e53d3e9542784a82828170823409189e2018-10-01T00:00:00Zhttps://www.dovepress.com/analysis-of-real-world-treatment-patterns-in-a-matched-rheumatology-po-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA; 3Real World Value and Evidence, Janssen Scientific Affairs, Titusville, NJ, USA; 4Immunology Medical Affairs, Janssen Biotech Incorporated, Horsham, PA, USA; 5Health Economics and Outcomes Research, Jassen Scientific Affairs, LLC, Horsham, PA, USA; 6Department of Rheumatology, Guven Hospital, Ankara, Turkey Purpose: This study compared treatment patterns of Turkish patients with a diagnosis of rheumatoid arthritis (RA) who were treated with innovator Remicade® (infliximab [IFX]) and either continued IFX or switched to CT-P13. Materials and methods: Adult RA patients with ≥1 IFX claim were identified from the Turkish Ministry of Health database. Eligible patients initiated and continued IFX treatment (continuers cohort [CC]) or initiated IFX and switched to CT-P13 (switchers cohort [SC]) during the study period. The initial IFX claim date was defined as the index date. The switch/reference date was defined as the CT-P13 switch date for the SC or a random IFX date during the period of CT-P13 availability for the CC. Cohorts were matched by age, sex, and number of IFX prescriptions during baseline. Patient demographics, discontinuation, and switching were summarized. The baseline period was defined as the period from the index date to the switch/reference date. The follow-up period ranged from the switch/reference date to the end of data availability. Results: After matching, 697 patients were selected: 605 patients for the CC and 92 patients for the SC. Mean IFX duration for the baseline period was 422 days in the CC and 438 days in the SC. Median time on any infused tumor necrosis factor (TNF) antagonist therapy was 1,080 days in the CC and 540 days in the SC during the study period. During the follow-up period, discontinuation was lower in the CC (CC=33.9% vs SC=87.5%; P<0.001). The mean time to discontinuation was longer in the CC (CC=276 days vs SC=132 days; P<0.001). A switch to another biologic medication during the follow-up period was observed in 19.0% of patients in the CC (n=115) and 81.5% of patients in the SC (n=75; P<0.001). Conclusion: Treatment patterns differed between patients prescribed IFX and CT-P13. In Turkey, RA patients maintained on IFX had greater treatment persistence (ie, fewer and later discontinuations) than those who initiated IFX and switched to CT-P13. Keywords: rheumatoid arthritis, biosimilar, CT-P13, continuer, treatment patterns, discontinuationYazici YXie LOgbomo AEllis LAGoyal KTeeple ASimsek IDove Medical Pressarticlerheumatoid arthritisbiosimilarCT-P13continuertreatment patternsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 127-134 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis biosimilar CT-P13 continuer treatment patterns Medicine (General) R5-920
spellingShingle	rheumatoid arthritis biosimilar CT-P13 continuer treatment patterns Medicine (General) R5-920 Yazici Y Xie L Ogbomo A Ellis LA Goyal K Teeple A Simsek I Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
description	Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA; 3Real World Value and Evidence, Janssen Scientific Affairs, Titusville, NJ, USA; 4Immunology Medical Affairs, Janssen Biotech Incorporated, Horsham, PA, USA; 5Health Economics and Outcomes Research, Jassen Scientific Affairs, LLC, Horsham, PA, USA; 6Department of Rheumatology, Guven Hospital, Ankara, Turkey Purpose: This study compared treatment patterns of Turkish patients with a diagnosis of rheumatoid arthritis (RA) who were treated with innovator Remicade® (infliximab [IFX]) and either continued IFX or switched to CT-P13. Materials and methods: Adult RA patients with ≥1 IFX claim were identified from the Turkish Ministry of Health database. Eligible patients initiated and continued IFX treatment (continuers cohort [CC]) or initiated IFX and switched to CT-P13 (switchers cohort [SC]) during the study period. The initial IFX claim date was defined as the index date. The switch/reference date was defined as the CT-P13 switch date for the SC or a random IFX date during the period of CT-P13 availability for the CC. Cohorts were matched by age, sex, and number of IFX prescriptions during baseline. Patient demographics, discontinuation, and switching were summarized. The baseline period was defined as the period from the index date to the switch/reference date. The follow-up period ranged from the switch/reference date to the end of data availability. Results: After matching, 697 patients were selected: 605 patients for the CC and 92 patients for the SC. Mean IFX duration for the baseline period was 422 days in the CC and 438 days in the SC. Median time on any infused tumor necrosis factor (TNF) antagonist therapy was 1,080 days in the CC and 540 days in the SC during the study period. During the follow-up period, discontinuation was lower in the CC (CC=33.9% vs SC=87.5%; P<0.001). The mean time to discontinuation was longer in the CC (CC=276 days vs SC=132 days; P<0.001). A switch to another biologic medication during the follow-up period was observed in 19.0% of patients in the CC (n=115) and 81.5% of patients in the SC (n=75; P<0.001). Conclusion: Treatment patterns differed between patients prescribed IFX and CT-P13. In Turkey, RA patients maintained on IFX had greater treatment persistence (ie, fewer and later discontinuations) than those who initiated IFX and switched to CT-P13. Keywords: rheumatoid arthritis, biosimilar, CT-P13, continuer, treatment patterns, discontinuation
format	article
author	Yazici Y Xie L Ogbomo A Ellis LA Goyal K Teeple A Simsek I
author_facet	Yazici Y Xie L Ogbomo A Ellis LA Goyal K Teeple A Simsek I
author_sort	Yazici Y
title	Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
title_short	Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
title_full	Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
title_fullStr	Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
title_full_unstemmed	Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
title_sort	analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/e53d3e9542784a82828170823409189e
work_keys_str_mv	AT yaziciy analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT xiel analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT ogbomoa analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT ellisla analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT goyalk analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT teeplea analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab AT simseki analysisofrealworldtreatmentpatternsinamatchedrheumatologypopulationthatcontinuedinnovatorinfliximabtherapyorswitchedtobiosimilarinfliximab
_version_	1718399252545142784

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Ejemplares similares